Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes.
Goldenberg RM, Steen O. Goldenberg RM, et al. Can J Diabetes. 2019 Mar;43(2):136-145. doi: 10.1016/j.jcjd.2018.05.008. Epub 2018 Jun 5. Can J Diabetes. 2019. PMID: 30195966 Free article. Review.
The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program for semaglutide comprises 6 pivotal global phase 3a trials (SUSTAIN 1 through 6) and 2 Japanese phase 3a trials. ...This artic …
The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program for semaglu …
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.
Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD. Kim N, et al. J Manag Care Spec Pharm. 2022 Jul;28(7):740-752. doi: 10.18553/jmcp.2022.28.7.740. J Manag Care Spec Pharm. 2022. PMID: 35737858 Free PMC article.
BACKGROUND: The rising prevalence and associated public health burden of obesity has led to advancements in pharmaceuticals for weight management. Semaglutide 2.4 mg, an anti-obesity medication (AOM) recently approved by the US Food and Drug Administration, has demonstrate …
BACKGROUND: The rising prevalence and associated public health burden of obesity has led to advancements in pharmaceuticals for weight manag …
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Powell J, Piszczatoski C, Taylor JR. Powell J, et al. Clin Ther. 2020 Oct;42(10):2100-2116. doi: 10.1016/j.clinthera.2020.07.017. Epub 2020 Aug 29. Clin Ther. 2020. PMID: 32873415 Review.
The purpose of this article was to review the pharmacology, clinical trials, safety profile, along with recommended dosing and costs, of oral semaglutide used for managing patients with T2DM. ...FINDINGS: Three Phase II studies of the pharmacokinetic properti …
The purpose of this article was to review the pharmacology, clinical trials, safety profile, along with recommended dosing and …
Confirmatory psychometric evaluations of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT).
Kolotkin RL, Williams VSL, von Huth Smith L, Meincke HH, Qin S, Williams N, Fehnel SE. Kolotkin RL, et al. Clin Obes. 2021 Oct;11(5):e12477. doi: 10.1111/cob.12477. Epub 2021 Jul 22. Clin Obes. 2021. PMID: 34296522 Free PMC article.
The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) was developed to assess weight-related physical and psychosocial functioning in the context of clinical trials. Data from two pivotal trials of once-week …
The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) was developed to assess weight-related ph …